Canaquest - Recent developments

SHARE
Aug. 5, 2022

Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September.

Our first Clinical Study at OBI already achieved a 20% reduction in seizures……..we believe we can do better with our more concentrated formula.

Nutraceutical: Our e-commerce site is live now and Mentanine and Omega-3 Index Booster (high concentration of DHA/EPA) have been produced in California and are available for sale in the US and for export.

We are receiving very positive preliminary testimony from our new formulated product, Mentanine (CBD isolate + Omega-3s - DHA, EPA formula)…….all natural.

Users have reported increased mental clarity, better sleep, more energy, and less brain fog and joint stiffness, which supports the pre-clinical trial results we obtained at Western University.

Contact supplier

Drop file here or browse